Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations.
The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday.
Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said.
Photo: Sam Yeh, AFP
The company enrolled its first participant for the phase 3 trials in April 2019 and completed the enrollment of all participants in December that year, it said.
Participants were recruited in a randomized, double-blinded and placebo-controlled study, it added.
Participants were divided into three age groups: two months to six months old, six months to two years old, and two years to six years old, Medigen said.
The number of infants from two months to six months old accounted for 25 percent of all participants, it said.
The results showed the drug’s safety and tolerance were good, even for young participants, and there was no significant difference in safety and tolerance between participants who were given the vaccine and those who received a placebo, the company said.
As for immunogenicity, results showed that the seroprotection rates 28 days, six months and one year after two EV71 vaccination doses were higher than health authorities’ requirements, it said. The seroprotection rates refer to the degree of antibody prevalence.
In terms of efficacy, Medigen said that the experimental drug offered statistically significant protection against the enterovirus under the Poisson regression model.
As enterovirus infections are popular in Taiwan, China and Southeast Asia, the company hopes its vaccine can hit the market soon, as there are no EV71 vaccine products available in other parts of the world, except for China.
At present, only three Chinese manufacturers have launched enterovirus vaccines to be marketed locally in China, Medigen said.
Those vaccines are suitable for children over the age of six months, it said.
In 2018, the market sales of China’s EV71 vaccines reached more than NT$30 billion (US$1.08 billion), and about 21 million doses were sold per year on average in the past three years, Medigen said.
The company on June 10 reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine. It has applied to the Food and Drug Administration for emergency use authorization and is preparing to conduct phase 3 trials abroad.
South Korea would avoid capitalizing on China’s ban on a US chipmaker, seeing the move by Beijing as an attempt to drive a wedge between Seoul and Washington, a person familiar with the situation said. The South Korean government would not encourage its memorychip firms to grab market share in China lost by Micron Technology Inc, which has been barred for use in critical industries by Beijing on national security grounds, the person said. China is the biggest market for South Korea semiconductor firms Samsung Electronics Co and SK Hynix Inc and home to some of their factories. Their operations in China
GEOPOLITICAL RISKS: The company has a deep collaboration with TSMC, but it is also open to working with Samsung Electronics Co and Intel Corp, Nvidia’s CEO said Nvidia Corp, the world’s biggest artificial intelligence (AI) GPU supplier, yesterday said that it is diversifying its supply chain partners in order to enhance supply chain resilience amid geopolitical tensions. “All of our supply chain is designed for maximum diversity and redundancy so that we can have resilience. Our company is very big and so we have a lot of customers depending on us. And so our supply chain resilience is very important to us. We manufacture in as many places as we can,” Nvidia founder and chief executive officer Jensen Huang (黃仁勳) said in response to a reporter’s question in
DIVERSIFICATION: The chip designer expects new non-smartphone products to be available next year or in 2025 as it seeks new growth engines to broaden its portfolio MediaTek Inc (聯發科) yesterday said it expects non-mobile phone chips, such as automotive chips, to drive its growth beyond 2025, as it pursues diversification to create a more balanced portfolio. The Hsinchu-based chip designer said it has counted on smartphone chips, power management chips and chips for other applications to fuel its growth in the past few years, but it is developing new products to continue growing. “Our future growth drivers, of course, will be outside of smartphones,” MediaTek chairman Rick Tsai (蔡明介) told shareholders at the company’s annual general meeting in Hsinchu City. “As new products would be available next year
BIG MARKET: As growth in the number of devices and data traffic accelerates, it will not be possible to send everything to the cloud, a Qualcomm executive said Qualcomm Inc is betting the future of artificial intelligence (AI) will require more computing power than what the cloud alone can provide. The world’s largest maker of smartphone processors is transitioning from a communications company into an “intelligent edge computing” firm, Qualcomm senior vice president Alex Katouzian said. The edge in question is the mobile device that a user taps to access a network or service, and Katouzian used his time headlining one of the major keynote events at the Computex show in Taipei to make the case for how big a market that would be. The US company’s chips help smartphones harness